Shukra Pharmaceuticals Ltd
company logo

Shukra Pharmaceuticals Ltd

SHUKRAPHARMA Share Price

BSE:524632

31.89

-0.35 (-1.09%)

As on April 2, 2026 at 04:00 PM
Loading chart...

Performance

Loading performance...

32.24

31.85

254585

0.81

1

Fundamentals

1,396.40Cr

47.60

21.22

0.06

0.67

0.03%

1.50

About

Shukra Pharmaceuticals Limited, formerly known Relish Pharmaceuticals Limited was established in March, 1993 and later on the Company name was changed from Relish Pharmaceuticals Limited to Shukra Pharmaceuticals Limited effective on September 22, 2016. The Company is presently engaged in the business of manufacturing and trading of pharmaceuticals formulations and laboratory testing. The company provides varieties of products to the clientele. Their product portfolio includes Antibiotics (Penicillin), Anti Biotics (Cephalosporin), Anti Biotics, Macrolides, Quinolones, Anti Bacterial, Anti Fungal, Anti Malarial, Anti Viral, Anti Protozoal, Anti Anthelmintic, Sedative and Tranquilliser, Anti Depressant, Anti Manic, Anti Emetic, Anti Ulcer, Beta Blockers, Diuretics, Analgesic, Analgesic (NASID), Muscle Relaxants, Anti Tuberculosis, Vitamin Products, Anti Allergics, Corticosteroids, Hyper and Hypoglycemic, Others. The company has four manufacturing divisions namely tablets (General and Beta Lactum) Capsules (General and Beta Lactum), Liquid and small volume parental. Their manufacturing unit is located at Rakanpur in Gujarat. The company customers include leading Manufacturers like Cadila Healthcare Limited (Zydus), Intas Pharmaceuticals Limited, Cadila Pharmaceuticals Limited, Makers Laboratories Limited, Agenta Pharma Limited etc. The company has assisted in the development and manufacture of a wide variety of drugs and dosage forms and potency variations for many prestigious pharmaceuticals companies around the world. In FY 2013-14, the Company got approval from Hon'ble High Court of Gujarat for revival of Relish Pharmaceuticals Limited and Amalgamation of Proper Dealcomm Private Limited with the erstwhile Relish Pharmaceuticals Limited and Re-organization of Share Capital of Relish Pharmaceuticals Limited through the Scheme of Arrangement vide Hon'ble High Court of Gujarat order dated 20 December, 2013. The Company has achieved WHO-GMP certification, successfully securing a partnership with Meril Healthcare for robotic surgery projects in October 2025.

Dakshesh Shah

1993

NameDesignation
Dakshesh ShahChairman / Executive Director / Managing Director
Payal MehtaExecutive Director
Dhruvin ShahE D & Wholetime Director
Sanskruti PatelE D & Wholetime Director
Pinki Nirmal SagarIndependent Non Exe. Director
Sonal Deepalbhai GandhiIndependent Non Exe. Director
Sarjeevan SinghIndependent Non Exe. Director
Jitendra shahIndependent Non Exe. Director
Anar Jayesh PatelExecutive Director / Whole Time Director / CFO
SHITAL DAKSHESH SHAHE D & Wholetime Director
Ritu KapoorIndependent Non Exe. Director
Arpita KabraaCompany Sec. & Compli. Officer

Shukra Pharmaceuticals Ltd FAQs

How do I Buy Shukra Pharmaceuticals Ltd Shares?

close

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Shukra Pharmaceuticals Ltd shares in BlinkX.

What is the Share Price of Shukra Pharmaceuticals Ltd?

close

The share price of any stock is volatile and changes during the day due to a variety of variables. Shukra Pharmaceuticals Ltd's share price is ₹31.89 as of 2026-04-05.

What is the PE ratio of Shukra Pharmaceuticals Ltd?

close

Shukra Pharmaceuticals Ltd's P/E ratio is 47.6 times as of 2026-04-05.

What is the PB ratio of Shukra Pharmaceuticals Ltd?

close

Shukra Pharmaceuticals Ltd's most recent financial reports indicate a price-to-book ratio of 21.22, showing the company's stock market valuation in relation to the value of its real assets.

What is the Market Cap of Shukra Pharmaceuticals Ltd?

close

Market capitalization, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Shukra Pharmaceuticals Ltd's market capitalization is ₹1396.4 Cr as on 2026-04-05.

What is the ROE of Shukra Pharmaceuticals Ltd?

close

The current financial records of Shukra Pharmaceuticals Ltd show a 15.9% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

What is the Total Asset of Shukra Pharmaceuticals Ltd?

close

According to Shukra Pharmaceuticals Ltd's most recent financial filings, the company has a total asset value of ₹65.43, which includes current and non-current assets such as inventory, cash, properties, and equipment.

What is the 52-week high and Low of Shukra Pharmaceuticals Ltd?

close

The 52-week high/low price of a Shukra Pharmaceuticals Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Shukra Pharmaceuticals Ltd's 52-week high and low as of 2026-04-05 are ₹65.26 and ₹11.74, respectively.